Articles citing this paper

Laszlo Otvos, Ph.D., is the President of OLPE, LLC, a US-based pharmaceutical consulting firm. His main clients are Arrevus, Inc. and Allysta Inc., biotechnology companies that license his adipokine receptor response modifier and host defence peptide patents from Temple University. Dr Otvos is a senior consultant to Arrevus and Allysta. He also serves as an Adjunct Professor for Semmelweis University, Hungary, and Associate Editor for Frontiers in Chemical Biology. Dr Otvos is an author of over 250 peer-reviewed publications with a current h-factor of 63. His main goal is to bring as many peptide drugs to market as possible, either through personal involvement in the preclinical development process or through editorial and public educational activities.